home about What's New lecture topics contact writings dialog contact

Goldsmith on Reducing Inappropriate Imaging Use in New England Journal of Medicine

Jeff Goldsmith and Bruce Hillman, MD. published an article on “The Uncritical Use of High Tech Imaging” in the July 1 issue of the New England Journal of Medicine. The article reviews some of the sources of excess demand for expensive imaging examinations, and how improvements in how medical students and residents are taught to use imaging could help promote more cost effective use of these expensive tools. This article highlights some of the themes of the forthcoming Hillman and Goldsmith book, The Sorcerer’s Apprentice: How Imaging is Reshaping Health Care, which will be published by Oxford University Press in September.

Goldsmith Does Webcast for The Harvard Business Review on Healthcare’s Innovation Drought

On April 26, Jeff Goldsmith did a Webcast on the innovation drought in US healthcare for The Harvard Business Review. For the last three decades of the 20th Century, medical technology is one of the great success stories of the US health system. Yet during the past ten years, the pharmaceutical and biotechnology industries, healthcare information technology and medical device industries all hit a lengthening flat spot, producing markedly fewer breakthrough technologies. What has happened to the US medical technology field and what can be done to foster innovation in this important sector of the US economy? Is consistent production of innovative medical technology consistent with an equity ownership model? Can medical technology firms harness the creativity of Gen X and Gen Y scientists and engineers? Who’s doing it right?

Goldsmith keynotes Drug Information Association on Comparative Effectiveness Research

On June 15, Jeff Goldsmith keynoted an international meeting of drug researchers on the new federal push under health reform for comparative effectiveness evaluations of drugs and medical technology in Washington DC. He also chaired a panel which included Mark McClellan, former FDA Commissioner and Sir Michael Rawlins, head of the British National Health Services’ National Institute for Health and Clinical Excellence (NICE) on how to use scientific information to make better decisions to cover and pay for health care innovation. The central thrust of the keynote was that unless consumers and patients believed the research would help them make better decisions about their own health, there would be no political support for comparative effectiveness research.

» Previous What's New Article